Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer

被引：4
|
作者：
de Wit, Ronald [1 ]
Tombal, Bertrand [2 ]
Freedland, Stephen [3 ,4 ]
机构：
[1] Erasmus Univ, Med Ctr, Med Oncol, Rotterdam, Netherlands
[2] Catholic Univ Louvain, Inst Rech Clin, Louvain, Belgium
[3] Cedars Sinai Med Ctr, Div Urol, Los Angeles, CA 90048 USA
[4] Durham VA Med Ctr, Sect Urol, Durham, NC USA
来源：
EUROPEAN UROLOGY | 2021年 / 79卷 / 02期
关键词：
INCREASED SURVIVAL; ENZALUTAMIDE; ABIRATERONE;
D O I：
10.1016/j.eururo.2020.10.016
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：170 / 172
页数：3
相关论文
共 50 条
  • [41] Targeted therapies and companion biomarkers in metastatic prostate cancer
    Auclin, E.
    Vano, Y. -A.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2014, 38 (01): : 31 - 37
  • [42] Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer
    Hahn, Andrew W.
    Hale, Peter
    Rathi, Nityam
    Agarwal, Neeraj
    CURRENT OPINION IN UROLOGY, 2017, 27 (06) : 559 - 565
  • [43] Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors
    Yazgan, Sati Coswn
    Yekeduz, Emre
    Utkan, Gungor
    Urun, Yuksel
    PROSTATE, 2022, 82 (15) : 1456 - 1461
  • [44] Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy
    Sen, Ishita
    Thakral, Parul
    Tiwari, Priya
    Pant, Vineet
    Das, Subha Shankar
    Manda, Divya
    Raina, Vinod
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (07) : 794 - 810
  • [45] Chemotherapy for metastatic castrate-sensitive prostate cancer
    Miller, R. E.
    Sweeney, C. J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (02) : 139 - 144
  • [46] Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate
    Giacinti, Silvana
    Carlini, Paolo
    Roberto, Michela
    Bassanelli, Maria
    Strigari, Lidia
    Pavese, Francesco
    Aschelter, Anna M.
    Felici, Alessandra
    Valeriani, Maurizio
    Cognetti, Francesco
    Marchetti, Paolo
    ANTI-CANCER DRUGS, 2017, 28 (01) : 110 - 115
  • [47] Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer
    Zsofia, Kueronya
    Krisztina, Biro
    Fruzsina, Gyergyay
    Lajos, Geczi
    ORVOSI HETILAP, 2017, 158 (02) : 42 - 49
  • [48] New treatment options for patients with metastatic prostate cancer
    Snoeks, L. L.
    Ogilvie, A. C.
    van Haarst, E. P.
    Siegert, C. E. H.
    NETHERLANDS JOURNAL OF MEDICINE, 2013, 71 (06) : 290 - 294
  • [49] Metastatic prostate cancer. Update: position paper for the use of chemotherapy
    Ohlmann, C. -H.
    Goebell, P. J.
    Grimm, M. -O.
    Klier, J.
    Koenig, F.
    Machtens, S.
    Schostak, M.
    Schrader, A. -J.
    Albers, P.
    UROLOGE, 2017, 56 (12): : 1597 - 1602
  • [50] ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling
    Liu, Chengfei
    Armstrong, Cameron M.
    Ning, Shu
    Yang, Joy C.
    Lou, Wei
    Lombard, Alan P.
    Zhao, Jinge
    Wu, Chun-Yi
    Yu, Aiming
    Evans, Christopher P.
    Tepper, Clifford G.
    Li, Pui-kai
    Gao, Allen C.
    ONCOGENE, 2021, 40 (35) : 5379 - 5392
12345